A pragmatic, randomized, controlled study evaluating the impact of access to smoking cessation pharmacotherapy coverage on the proportion of successful quitters in a Canadian population of smokers motivated to quit (ACCESSATION)

Table 2 7-day point prevalence of abstinence from weeks 2 to 26 and complete abstinence rate from weeks 26 to 52 (intent-to-treat)

	Full coverage (n = 696), proportion of patients, %	No coverage (n = 684), proportion of patients, %	OR (95% CI)	p-value
7-day PPA
Week 2	18.8	13.3	1.59 (1.17–2.16)	0.003
Week 13	34.1	23.7	1.72 (1.35–2.20)	<0.001
Week 26	20.8	13.9	1.64 (1.23–2.18)	0.001
Week 26 (urine cotinine-confirmed)	15.7	10.1	1.68 (1.21–2.33)	0.002
CAR weeks 26–52	6.6	5.6	1.19 (0.76–1.87)	0.439

CI = confidence interval; CAR = complete abstinence rate; OR = odds ratio; PPA = point prevalence of abstinence.

ISSN: 1471-2458